bluebird bio: Scientific Success And Financial Success, And The Gap Between
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
FiercePharma2d
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Investor's Business Daily on MSN17h
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following ...
KFGO21h
Pfizer’s Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...
FiercePharma1d
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...
BioSpace15d
Vertex, CRISPR’s Casgevy Highlights Complex Path to Gene Therapy Profitability
No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...
Medpage Today on MSN23h
Sickle Cell Disease Drug Pulled From Global Markets
Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...
Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships make NTLA stock a ...
BioSpace1d
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...
The Pharma Letter2d
Lonza to produce Casgevy for Vertex
Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) has signed a long-term commercial supply ...
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Basel, Switzerland, 24 September 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply ...
Health Canada Oks Vertex's CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease
(VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of ...